VCG
ABBV icon

Vantage Consulting Group’s AbbVie ABBV Stock Holding History

Vantage Consulting Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,379
Closed -$237K – 7
2024
Q2 		$237K Buy
1,379
+49
+4% +$8.12K 0.18% 120
2024
Q1 		$242K Sell
1,330
-237
-15% -$40.8K 0.15% 137
2023
Q4 		$243K Buy
1,567
+9
+0.6% +$1.31K 0.16% 135
2023
Q3 		$232K Sell
1,558
-109
-7% -$16K 0.16% 139
2023
Q2 		$225K Buy
1,667
+67
+4% +$9.82K 0.13% 177
2023
Q1 		$255K Buy
1,600
+114
+8% +$17.4K 0.14% 142
2022
Q4 		$240K Sell
1,486
-332
-18% -$50.9K 0.14% 145
2022
Q3 		$244K Buy
1,818
+144
+9% +$20.7K 0.14% 127
2022
Q2 		$256K Buy
1,674
+135
+9% +$20.6K 0.14% 112
2022
Q1 		$249K Sell
1,539
-533
-26% -$77.4K 0.1% 142
2021
Q4 		$281K Sell
2,072
-205
-9% -$24.2K 0.08% 128
2021
Q3 		$246K Buy
2,277
+319
+16% +$36.5K 0.05% 133
2021
Q2 		$221K Buy
+1,958
New +$221K 0.04% 178
2021
Q1 		– Sell
-687
Closed -$74K – 106
2020
Q4 		$74K Buy
+687
New +$66K 0.01% 280

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Vantage Consulting Group's ABBV Position: Q3 2024 in Review

Vantage Consulting Group sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 1,379 shares — an estimated $237K sold.

Vantage Consulting Group first reported a position in ABBV in Q4 2020 and held it in 14 quarters. The position peaked at $281K in Q4 2021. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Vantage Consulting Group reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
  • Vantage Consulting Group sold 1,379 AbbVie shares in Q3 2024, an estimated $237K.
  • Vantage Consulting Group first reported a position in AbbVie in Q4 2020 and held it in 14 quarters.
  • Vantage Consulting Group's AbbVie position peaked at $281K in Q4 2021.
  • 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Vantage Consulting Group's 13F filing for Q3 2024, filed 14 Nov 2024.